The present disclosure provides use of a timosaponin enzymatically transformed product in preparation of drugs for inhibiting skin superficial fungi. In the use provided in the present disclosure, the timosaponin enzymatically transformed product is prepared by enzymatically transforming rhizoma anemarrhenae extract with -glucosidase or a compound enzyme of xylanase and cellulose after purification. In the present disclosure, as an active pharmaceutical ingredient for inhibiting skin superficial fungi, the timosaponin enzymatically transformed product has the minimum inhibitory concentration of 4 mg/L against fungi, which is obviously superior to total timosaponin in the bacteriostatic capability, and has a certain application prospect in the aspect of treating skin superficial mycoses.

The present invention relates to a composition for preventing and treating cancer-related fatigue, characterized by containing a new processed ginseng powder or a new processed ginseng extract having an increased amount of a ginsenoside constituent, which was previously minute, by preparing a saponin-decomposing enzyme and subsequently using hydrolysis by the prepared saponin-decomposing enzyme and an organic acid. The composition according to the present invention can be very effectively used for preventing and treating cancer-related fatigue, the most destructive and universal side effect, which is caused by cancer itself or occurs in association with the treatment of cancer.

The present invention relates to a composition for preventing and treating cancer-related fatigue, characterized by containing a new processed ginseng powder or a new processed ginseng extract having an increased amount of a ginsenoside constituent, which was previously minute, by preparing a saponin-decomposing enzyme and subsequently using hydrolysis by the prepared saponin-decomposing enzyme and an organic acid. The composition according to the present invention can be very effectively used for preventing and treating cancer-related fatigue, the most destructive and universal side effect, which is caused by cancer itself or occurs in association with the treatment of cancer.

Methods and materials for enzymatic synthesis of mogroside compounds described.

Methods and materials for enzymatic synthesis of mogroside compounds described.

To provide a mogrol glycosyltransferase and a method for producing a mogrol glycoside using the enzyme. The present invention provides a mogrol glycosyltransferase and a method for producing a mogrol glycoside using the enzyme, and a transformant into which a mogrol glycosyltransferase gene is introduced and a method for preparing the transformant.

To provide a mogrol glycosyltransferase and a method for producing a mogrol glycoside using the enzyme. The present invention provides a mogrol glycosyltransferase and a method for producing a mogrol glycoside using the enzyme, and a transformant into which a mogrol glycosyltransferase gene is introduced and a method for preparing the transformant.

The present invention relates to a method for increasing the content of mogroside V in Siraitia grosvenorii suspended cells. In the method, 10-200 mg/L of a yeast inducer and 50-260 mg/L of methyl jasmonate are respectively added on days 5 to 11 of the culture cycle of Siraitia grosvenorii suspended cells, thereby increasing the synthesis rate and yield of mogroside V, and also reducing the amount of mogroside II secreted. The method is beneficial for the market-oriented and large-scale production and quality control management of mogroside V.

The present invention relates to a method for increasing the content of mogroside V in Siraitia grosvenorii suspended cells. In the method, 10-200 mg/L of a yeast inducer and 50-260 mg/L of methyl jasmonate are respectively added on days 5 to 11 of the culture cycle of Siraitia grosvenorii suspended cells, thereby increasing the synthesis rate and yield of mogroside V, and also reducing the amount of mogroside II secreted. The method is beneficial for the market-oriented and large-scale production and quality control management of mogroside V.

The invention relates to recombinant microorganisms and methods for producing mogroside compounds and mogroside precursors.